- Generative protein design model focus
- Concentrates on drug discovery depth over broad coverage
- Scales to organization-wide healthcare rollouts
Latent Labs
Generative protein design model research
SF6.9
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Identify drug targets from biology dataProtein design and biotech researchers
Identify drug targets from biology dataProtein design and biotech researchers
Best for
Protein design and biotech researchers
Pricing
Custom
SoftFinders Score
6.9 / 10
Overview
What is Latent Labs?
Latent Labs is an AI biology company building generative models for protein design aimed at programmable biology research. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
Latent Labs works best for protein design and biotech researchers, and its edge is generative protein design model focus. The honest trade-off here: early-stage and research-facing today. Pricing is sales-led and scoped per buyer rather than posted publicly. Run a small pilot to confirm fit before committing to a wider rollout.
KEY FEATURES
What you get out of the box
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
Target Discovery
Identifies potential drug targets from biological data
Molecule Design
Generates and ranks small molecule candidates
USE CASES
Where teams put it to work
Identify drug targets from biology data
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Editorial Take
What we like, and what to verify
- Early-stage and research-facing today in most deployments
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ